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The clinical outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is
strongly influenced from the potential complications arising during the delicate phase of
post-transplant immune restoration. The quantitative aspects of immune-cell repopulation
after HSCT and the qualitative features their functional restitution have been extensively
reported. Nevertheless, measurable immune biomarkers predicting the clinical outcome
of HSCT await formal validation. The aim of this review is an appraisal of most studies
published so far on the predictive value of different T and NK-cell biomarkers after HSCT
with emphasis on defined thresholds endorsed by multivariate analysis.
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INTRODUCTION
The restoration of a functional immune system is one of the main
factors influencing the clinical outcome of allogeneic hematopoi-
etic stem cell transplantation (HSCT). The post-transplant period
is characterized by multiple immune defects that expose the
patient to a high risk of opportunistic infections and, eventually,
disease relapse. The duration of this period may vary accord-
ing to several variables, including patient age and immune status
before transplant, the degree of donor compatibility, the intensity
of the conditioning regimen, the source of stem cells, eventual
graft manipulation, and pharmacological immune suppression.
The normalization of granulocytes, monocytes, and NK-cell num-
bers usually occurs within the first weeks and, with the possible
exception of NK-cells, coincides with their full competence. Con-
versely, the normalization of T and B cell numbers may take much
longer and does not necessarily associate with their immediate
functional restitution (Shiobara et al., 1982). Although often used
interchangeably, it is therefore important to distinguish between
immune reconstitution, which refers to quantitative immune-
cell repopulation, and immune recovery, which pertains to their
qualitative restitution.
The quantitative reconstitution of T cells post-transplant
occurs through two main mechanisms: (i) the early peripheral
expansion of donor-derived memory T cells present in the graft,
which happens in weeks (ii) the late emergence of host-tolerant
naïve T cells originating from donor stem cells after thymic educa-
tion, which, depending on donor age, occurs in months (van den
Brink et al., 2004). The qualitative recovery of T cells may follow
their quantitative reconstitution with a delay of many years and
implies de novo pathogen encounter, with ensuing differentiation
into effector and memory T cells.
Although the quantitative aspects of immune reconstitution
post-transplant and the qualitative features of immune recovery
have been the subject of several studies, a tight association between
measurable immune biomarkers and the clinical outcome of
HSCT, is currently missing. So far, the specific issue of validating
thresholds of immune measurements that may help predicting the
incidence of major post-transplant events, such as opportunistic
infections, graft-versus-host disease (GVHD), and disease relapse,
has been approached by single-center, necessarily small-sized stud-
ies. While sometimes sufficiently powered to obtain statistically
significant results, these studies often failed to draw definitive con-
clusions that may be relevant to daily clinical practice. Conversely,
the lack of harmonized methods for immune biomarker measure-
ments and the great heterogeneity of the transplant populations
between the different studies have prevented from meaningful
meta-analysis.
The aim of this review is an appraisal of the studies published so
far on the predictive value of different T and NK-cell biomarkers
after HSCT with emphasis on the thresholds chosen for statistical
analysis. A comprehensive Table 1 detailing the main results from
the different studies has also been included. Descriptive studies
based on the comparison between different groups as the only sta-
tistical approach, studies in the setting of autologous HSCT and
immune biomarkers whose predictive value has not been endorsed
by multivariate analysis, have been purposely excluded from this
review.
T LYMPHOCYTES AND INVARIANT NKT CELLS
The absolute lymphocyte count (ALC) derived from routine
blood-cell testing has been the first immune biomarker explored
for predicting the clinical outcome of HSCT. In patients undergo-
ing T cell-depleted HSCT from an HLA-identical sibling (HLA-
sib), an ALC above the median [>690/µL (Montero et al.,
2006) or >450/µL (Savani et al., 2007a)] at day 30 post-
transplant was found to be independently associated with a lower
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Table 1 |T- and NK-cell biomarkers, thresholds, and clinical outcome after HSCT.
Biomarker Pts Donor Days Statistics Threshold Outcome Reference
ALC 138 HLA-sib +30 Median >690 cells/µL ↓TRM ↑LFS ↑OS Montero et al. (2006)
157 HLA-sib +30 Median >450 cells/µL ↓TRM ↓RI ↑OS Savani et al. (2007a)
102 MUD +30 Arbitrary >1000 cells/µL ↓TRM ↑LFS ↑OS Le Blanc et al. (2009)
65 Haplo UCB +60 Arbitrary >1000 cells/µL ↓TRM ↑OS Ciurea et al. (2011)
360 UCB +30 From Savani et al.
(2007a)
>200 cells/µL ↓TRM ↑LFS ↑OS Burke et al. (2011)
CD4+ T cells 69 HLA-sib MUD +90 Arbitrary (HIV) >200 cells/µL ↓TRM ↑OS ↓infect. Kim et al. (2006)
758 HLA-sib MUD +35 Median >86 cells/µL ↓TRM Berger et al. (2008)
345 HLA-sib MUD +90 From Matthews
et al. (2010)
>200 cells/µL ↓TRM Buhlmann et al.
(2011)
99 HLA-sib MUD +20 ROC >115 cells/µL ↓TRM Fedele et al. (2012)
CD8+ T cells 32 HLA-sib MUD +365 Arbitrary >V percentile ↑OS Koehl et al. (2007)
iNKT/T ratio 71 HLA-sib MUD +15 ROC >0.58×10−3 ↓aGVHD ↓TRM ↑OS Rubio et al. (2012)
22 Haplo +545 Median >10−4 No relapse Casorati et al. (2012)
TREC values 102 HLA-sib Pre-tx Categories 172/150,000 T ↑OS ↓infections Clave et al. (2005)
33 Haplo +180 Categories sj<0.1/150,000 T;
β<0.001/150,000 T
↑RI Clave et al. (2012)
Tregs
frequencies
60 HLA-sib MUD aGVHD Median >0.5% over TNC ↓TRM ↑OS Magenau et al.
(2010)
57 HLA-sib MUD cGVHD Categories >3% over PBL No cGVHD Koreth et al. (2011)
CMV-specific
CD8+ T cells
24 HLA-sib MUD +100 Arbitrary >10 tet+ cells/µL No CMV disease Cwynarski et al.
(2001)
83 HLA-sib MUD +65 Categories >7 tet+ cells/µL ↓CMV disease Gratama et al. (2010)
133 HLA-sib MUD
UCB
+120 Categories >1 cyt+ cells/µL ↓CMV DNAemia Tormo et al. (2011)
131 HLA-sib MUD
Haplo
+365 ROC >3 cyt+ cells/µL No CMV DNAemia Lilleri et al. (2012)
CMV-specific
CD4+ T cells
30 HLA-sib MUD +120 Arbitrary >2.5 S.I. ↓CMV disease Krause et al. (1997)




+120 Categories >1.2 cyt+ cells/µL ↓CMV DNAemia Tormo et al. (2011)
117 UCB +30 Arbitrary >7 S.I. No infections ↑ LFS Parkman et al. (2006)
131 HLA-sib MUD
Haplo
+365 ROC >1 cyt+ cells/µL No CMV DNA Lilleri et al. (2012)
EBV-specific T
cells
33 MUD +56 Categories >1 cyt+ cells/µL No relapse Hoegh-Petersen
et al. (2012)
NK-cells 43 Haplo +15 Median >9.27 cells/µL ↑LFS Chang et al. (2008)
54 HLA-sib +30 Median >150 cells/µL ↓TRM ↓RI ↑OS
↓aGVHD
Savani et al. (2007b)
345 HLA-sib MUD +365 From Ruggeri
et al. (2002)
>150 cells/µL ↓TRM Buhlmann et al.
(2011)
ALC, absolute lymphocyte count; HLA-sib, HLA-identical sibling; TRM, transplant-related mortality; LFS, leukemia-free survival; OS, overall survival; RI, relapse inci-
dence; MUD, matched unrelated donor; Haplo, HLA-haploidentical; UCB, umbilical cord-blood; ROC, receiver operating characteristic curve analysis; aGVHD, acute
graft-versus-host-disease; TREC, T cell receptor excision circles; pre-tx, pre-transplant; TNC, total nucleated cells; cGVHD, chronic graft-versus-host-disease; PBL,
peripheral blood lymphocytes; Tet+, tetramer-positive cells; cyt+, intracellular cytokine-positive; S.I., stimulation index.
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transplant-related mortality (TRM) and longer leukemia-free sur-
vival (LFS) and overall survival (OS). The association between an
higher ALC at early time points after transplant and a favorable
clinical outcome was confirmed by taking an arbitrary thresh-
old of 1000/µL in T cell-replete HSCT from matched unrelated
donors (MUD) (Le Blanc et al., 2009) and CD34-selected HSCT
form HLA-haploidentical donors (Ciurea et al., 2011), or by taking
an arbitrary threshold of 200/µL in umbilical cord-blood (UCB)
transplantation (Burke et al., 2011). Investigating the same issue
in patients that received a reduced-intensity regimen, however,
has found conflicting results (Matthews et al., 2010; Burke et al.,
2011), suggesting that the type of conditioning may influence the
predictive value of the ALC.
The predictive value of T lymphocyte subsets assessed by flow
cytometry, rather than the simpler ALC, has been examined in
more sophisticated studies. At day 90 after T cell-replete HSCT
form a HLA-sib or a MUD, a CD4+ T cell count above 200/µL, a
threshold derived from the HIV field, was independently asso-
ciated with a lower NRM, less opportunistic infections, and a
longer OS (Kim et al., 2006). The role for a rapid reconstitution of
CD4+ T cells in protecting from transplant morbidity and mor-
tality was confirmed in three subsequent studies using slightly
different approaches for statistical analysis. The first study found
that at day 30 post-transplant, a CD4+ T cell count above the
median (>86/µL) was associated with a lower TRM (Berger et al.,
2008). The second study confirmed the association and observed
no impact on relapse incidence (Buhlmann et al., 2011). The third
study used receiver operator curve (ROC) analysis of CD4+ T cell
counts at day 20 post-transplant for determining a threshold of
115/µL, which was retrospectively found to be associated with a
lower TRM (Fedele et al., 2012).
Differently from CD4+ T cells, the predictive value of CD8+ T
cell biomarkers is less studied. In a combined series of HLA-sib,
MUD, or HLA-haploidentical pediatric HSCT, reaching a CD8+
T cell count above the fifth percentile of age-matched controls
within the first year post-transplant was found to be indepen-
dently associated with a longer OS and a trend toward a lower
relapse incidence (Koehl et al., 2007).
The pattern of invariant natural killer T cells (iNKT) recon-
stitution has been explored for predicting the clinical outcome at
earlier time points after HSCT and independently from conven-
tional T cells. The reconstitution of iNKT cells after HLA-sib or
MUD HSCT was found to precede that of T and NK-cells (Rubio
et al., 2012). Accordingly, at day 15 post-transplant an iNKT/T cell
ratio above 0.58× 10−3, a threshold identified after retrospective
ROC analysis, was associated with a zero likelihood of GVHD.
Moreover, reaching an iNKT/T cell ratio above 10−3 within the
first 3 months after transplantation was independently associated
with a lower NRM and a longer OS. In a concomitant study, reach-
ing an NKT/T cell ratio above 10−4 within the first 18 months
after CD34-selected HLA-haploidentical pediatric HSCT associ-
ated with the maintenance of disease remission in all children (de
Lalla et al., 2011; Casorati et al., 2012).
TREC ANALYSIS
The molecular analysis of TCR excision circles (TRECs) in circu-
lating T cells allows to quantitatively assess host thymic function,
a parameter that has been shown to play a fundamental role in
the rapidity of T cell immune reconstitution after HSCT (Talven-
saari et al., 2002). After categorization of data from a retrospective
cohort, the group of Antoine Toubert has prospectively shown
that a pre-transplant TREC content above the threshold of 172
per 150,000 CD3+ T cells is an independent factor associated with
less infections, including Cytomegalovirus (CMV) reactivation,
and a longer OS after T cell-replete HLA-sib HSCT (Clave et al.,
2005). The same group has found that at 6 months after CD34-
selected HLA-haploidentical pediatric HSCT, a TREC value below
detection levels (<0.1 per 150,000 CD3+ T cells for sjTREC and
<0.001 per 150,000 CD3+ T cells for βTREC) was associated with
a higher relapse incidence (Clave et al., 2012).
NATURAL TREGS
In animal models of HSCT, natural regulatory T cells (Tregs) have
a key role in promoting tolerance and, in particular, in protecting
from GVHD (Nguyen et al., 2006). In humans, however, there are
a number of controversial issues that so far have prevented from
confirming the value of Tregs assessment for predicting the risk
of GVHD, its grading and response to therapy. These include how
to discriminate Tregs from activated T cells and what is the most
appropriate way to express Tregs measurements.
In patients with acute GVHD after HLA-sib or MUD HSCT,
Tregs frequencies measured at disease onset as the percentage of
CD4+CD25brightFoxp3+ T cells over total nucleated cells were
reported to inversely correlate with acute GVHD grading (Mage-
nau et al., 2010). Moreover, Tregs frequencies above the median,
i.e., >0.5%, were associated with complete response to first-line
therapy, resulting in a lower TRM and a longer OS. In another
study considering patients with gastrointestinal GVHD, however,
peripheral blood as well as mucosal Tregs frequencies, measured
as the percentage of CD4+ co-expressing Foxp3, were not found
to correlate with disease severity (Lord et al., 2011).
The evaluation of Tregs biomarkers for predictive purposes has
also yielded conflicting results in chronic GVHD. Some authors
have found a paradoxical increase in Tregs measured both as the
percentage and as the absolute count of CD4+CD25bright (Clark
et al., 2004). These T cells were later found to be suppressive ex
vivo, ruling out that they were activated T cells in disguise. On the
contrary, other authors have reported that Tregs frequencies mea-
sured as the percentage of CD4+CD25bright T cells over peripheral
blood lymphocytes below 3%, a threshold derived from linear
and logistic regression, were associated with chronic GVHD. This
threshold was derived from linear regression models based on data
from healthy donors (Zorn et al., 2005). In a phase I/II trial inves-
tigating the administration of low dose IL-2 in chronic GVHD,
the same group has found that changes in the median count of
Tregs somewhat correlated with the probability of responding to
the treatment (Koreth et al., 2011).
PATHOGEN-SPECIFIC T CELLS
The value of pathogen-specific T cell responses as an immune
biomarker predictive of the risk and the severity of opportunis-
tic infections after HSCT is still controversial. This is mostly due
to the use of different methods for measurement (MHC-peptide
tetramers, intracellular cytokine staining, ELISPOT assays) and
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to the lack of harmonized protocols between the different stud-
ies. Other contentious issues are whether it is sufficient assessing
either CD8+ or CD4+ responses or it is needed considering both,
and whether complex and costly biomarkers are worthy compared
with easier, cheaper, and already validated tests, such as serology
(Ljungman et al., 2003).
Since CMV disease is a major complication after HSCT, the
majority of the studies have focused their attention on CMV-
specific responses. In an early study investigating the use of
tetramers, it was found that reaching 10 CMV-specific CD8+ T
cells/µL within the first 100 days after HSCT from an HLA-id or
a MUD with discordant serology associated with a zero likelihood
of CMV disease (Cwynarski et al., 2001). The predictive value of
the CMV-specific CD8+ T cell count measured with tetramers was
confirmed in a multicenter, prospective study including HLA-sib
and MUD HSCT where, after categorization, it was found that
a value above the threshold of 7 cells/µL associated with a lower
incidence of CMV disease (Gratama et al., 2010).
Other studies have examined the predictive value of CMV-
specific CD4+ T cell responses showing comparable results. In
a pioneering study by the group of Hermann Einsele, it was found
that a positive CD4+ T cell proliferative response defined as a
stimulation index above the arbitrary value of 2.5 within the
first 120 days after HLA-sib or MUD HSCT associated with a
reduced incidence of CMV disease (Krause et al., 1997). The pre-
dictive value of studying CD4+ T cell responses was confirmed by
using intracellular cytokine staining. In a similar setting, reach-
ing 0.4 CMV-specific CD4+ T cells/µL within day 30 and 50,
for example, was found to associate with complete prevention
from subsequent CMV reactivation (Pourgheysari et al., 2009).
In another study, a positive proliferative response to either CMV,
HSV, or VZV defined as a stimulation index above 7 was associ-
ated not only with a zero probability of opportunistic infections,
but also with the maintenance of disease remission, indicating
that the recovery of pathogen-specific immunity may serve as
a surrogate biomarker of immune restoration (Parkman et al.,
2006).
In certain studies, the concomitant exploration of both CD4+
and CD8+ CMV-specific T cells allowed determining the predic-
tive thresholds for the two subsets in a compared manner. In a
pediatric population, after ROC analysis of intracellular cytokine
staining data from a retrospective cohort (Lilleri et al., 2006), it was
found that reaching a CMV-specific T cell count above the thresh-
old of 1/µL for CD4+ T cells and of 3/µL for CD8+ T cells within
the first year after HLA-sib, MUD, or HLA-haploidentical pediatric
HSCT associated with a zero likelihood of CMV reactivation up to
2 years thereafter (Lilleri et al., 2012). These thresholds were found
to be remarkably similar (1.2 and 1/µL for CD4+ and CD8+ CMV-
specific T cells, respectively) in HLA-sib and MUD adult HSCT
(Tormo et al., 2011) suggesting that measuring pathogen-specific
responses in both subsets may be of predictive value, although
with slightly different thresholds.
The results of the studies on Epstein-Barr virus (EBV)-specific
responses are more controversial. Although measuring EBV-
specific T cell responses by intracellular cytokine staining was
found to have no value in predicting the likelihood of post-
transplant lymphoproliferative disease (Hoegh-Petersen et al.,
2011), finding at day 56 an EBV-specific T cell score above 1, a
threshold found after categorization of a complex measure includ-
ing CD4 and CD8 viral epitopes, was associated with a near-zero
likelihood of leukemia relapse (Hoegh-Petersen et al., 2012).
NK-CELLS
The discovery that NK alloreactivity plays a major role in pre-
venting disease relapse after CD34-selected HLA-haploidentical
HSCT (Ruggeri et al., 2002), has fostered a number of studies
investigating the predictive value of NK-cell biomarkers on clinical
outcome. The reconstitution of NK-cells post-transplant is slightly
slower compared to other cells of the innate immune system, but
definitively faster than conventional T cells. At 30 days after T
cell-depleted HLA-sib HSCT, an NK-cell count above the median
(>150/µL) was found to associate with less acute GVHD, a lower
relapse incidence, and a longer OS (Savani et al., 2007b). The asso-
ciation between higher NK-cell counts and lower relapse incidence
was however restricted to patients with myeloid leukemia, a dis-
ease that is susceptible to NK lysis. The predictive value of NK-cell
counts at early time points post-transplant was confirmed in the
setting of unmanipulated HLA-haploidentical HSCT, where, after
categorization, an NK-cell count above the threshold of 9.27/µL as
early as 15 days post-transplant was associated with a longer LFS
(Chang et al., 2008). The picture was shown to differ in the context
of T cell-replete HSCT, where higher NK-cell counts (>150/µL, a
threshold taken from previous studies (Savani et al., 2007b) were
associated with a lower TRM at late time points, but not with a
lower relapse incidence (Buhlmann et al., 2011).
CONCLUSION
In the era of predictive and molecular medicine, the practice
of HSCT is still characterized by many prognostic uncertain-
ties. Since many complications of HSCT derive from the state of
temporary, although often prolonged, state of immunodeficiency
post-transplant, it is clear that finding a tight correlation between
certain immune system defects and the different complications
may help predict the overall clinical outcome. This is impor-
tant not only for improving the care of patients, who may expect
benefits from ready and tailored strategies of intervention, such as
intensification or discontinuation of antimicrobial and immune
suppressive drugs, but also for establishing accepted surrogate
markers of immune restoration that may accelerate the clinical
development of novel transplant strategies, including the trans-
fer of pathogen-specific T cells generated after ex vivo stimulation
(Feuchtinger et al., 2010; Heslop et al., 2010).
The road leading to the validation of immune biomarkers
answering to this crucial, unmet need is long and winding, and is
possibly better traveled by joining forces in multicenter efforts.
The recent launch of different, retrospective, and prospective stud-
ies coordinated by the Immunobiology Working Party of the
European Bone Marrow Transplantation society goes exactly in
this direction and is expected to contribute to filling this gap in
the near future.
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